April 6, 2012 -- Zhejiang Hisun Pharmaceutical, a China company with numerous cross-border relationships, has successfully filed an Investigational New Drug application with the FDA in the US to begin clinical trials of an innovative cholesterol-lowering statin. Frontage Labs, a, CRO with operations in China and the US, completed the work on behalf of Hisun. Earlier this year, Hisun announced a $545 million generic drug JV with Pfizer. More details....
Stock Symbols: (SHA: 600267) (NYSE: PFE)
